Raharjo Budiono, Gunawan Catherine Keiko, Linggawan Stephani, Bintoro Siprianus Ugroseno Yudho, Sumarpo Anton
Faculty of Medicine, Universitas Wijaya Kusuma Surabaya, Surabaya, Indonesia.
Faculty of Medicine, Maranatha Christian University, Bandung, Indonesia.
J Med Life. 2025 Jun;18(6):600-603. doi: 10.25122/jml-2025-0020.
Lymphoblastic lymphoma (LBL) is a rare and aggressive lymphoblastic neoplasm, accounting for approximately 2% of non-Hodgkin lymphoma cases. Despite sharing clinical and morphological similarities with acute lymphoblastic leukemia (ALL), LBL is characterized by distinct genetic abnormalities. Due to the ambiguity surrounding treatments, the prognosis for LBL remains poor, with complete remission rates between 40-58% and 5-year disease-free survival rates between 36-70%. We present a case of a 42-year-old man diagnosed with B-acute lymphoblastic leukemia (B-ALL)/lymphoblastic lymphoma (LBL). The diagnosis was challenging due to the rarity of the condition and the overlapping features of LBL and ALL. This case report highlights the predominance of lymphoblasts and the presence of the p190 (e1a2) transcript, which is frequently associated with poor prognostic outcomes in lymphoblastic malignancies. The coexistence of both B-ALL and LBL underscores the necessity of a comprehensive understanding of the diagnostic approach, which is essential for optimizing treatment strategies and improving prognosis.
淋巴母细胞淋巴瘤(LBL)是一种罕见且侵袭性的淋巴母细胞肿瘤,约占非霍奇金淋巴瘤病例的2%。尽管LBL与急性淋巴细胞白血病(ALL)在临床和形态学上有相似之处,但其特征是具有独特的基因异常。由于治疗方面存在不确定性,LBL的预后仍然很差,完全缓解率在40%-58%之间,5年无病生存率在36%-70%之间。我们报告一例42岁男性被诊断为B-急性淋巴细胞白血病(B-ALL)/淋巴母细胞淋巴瘤(LBL)的病例。由于该疾病罕见以及LBL和ALL的特征重叠,诊断具有挑战性。本病例报告强调了淋巴母细胞的优势以及p190(e1a2)转录本的存在,这在淋巴母细胞恶性肿瘤中常与不良预后相关。B-ALL和LBL的共存凸显了全面理解诊断方法的必要性,这对于优化治疗策略和改善预后至关重要。